Share
USER HOTLINE: call us at +49 30 65499 145 | Not all products are available in the USA.
Search for ""
Search for ""
February 28, 2025
Extracorporeal Blood Purification in Septic Shock: A Review of the position paper by Bottari et al.

The Role of Extracorporeal Blood Purification Techniques in the Treatment of Septic Shock: a review based on the recent position paper by Bottari et al (1), with particular consideration of CytoSorb hemoadsorption therapy

read article
See all our Blog posts

Welcome to our Blog!

I want to welcome you to our official CytoSorbents Blog “Let’s talk…” and personally invite you to discuss and exchange opinions via this platform.

 

CytoSorbents’ adsorption technology represents a new approach to blood purification. As these new tools have to be used adequately to help patients in different situations, there is a need for continuous development and knowledge generation. Discussions, explanations, brainstorming and interaction in general can catalyze and accelerate this process. We will come up with interesting topics, new publications – which may even be controversial –, hypotheses, and food for thoughts to inspire and stimulate dialogue.

 

So, I want to invite all users of our products, interested healthcare professionals, researchers, thinkers, supporters, and especially critics to actively discuss and share your opinion on relevant topics to progress with the development of patient-centric precision therapy schemes.

 

I thank you in anticipation.

 

Christian

Picture of Dr. Christian Steiner
Christian Steiner, MD Executive Vice President of Sales and Marketing

All our Blog Posts

February 28, 2025
Extracorporeal Blood Purification in Septic Shock: A Review of the position paper by Bottari et al.

The Role of Extracorporeal Blood Purification Techniques in the Treatment of Septic Shock: a review based on the recent position paper by Bottari et al (1), with particular consideration of CytoSorb hemoadsorption therapy

read blog post
January 27, 2025
Prof. Daniel Wendt on the results of the second interim STAR Registry analysis

Prof Dr Daniel Wendt on the results of the second interim STAR Registry analysis: “Hemoadsorption appears to be a feasible, safe and potentially effective solution for reducing perioperative bleeding in patients on oral anticoagulants”

read blog post
July 08, 2024
Achieved: 1,000 entries in CytoSorb Literature Database

The CytoSorb Literature Database has just surpassed 1,000 entries – One thousand peer reviewed publications, poster presentations from national and international conferences and case reports from many different hospitals worldwide. As such, CytoSorb stands as the most researched and published hemoadsorption therapy of its kind.

read blog post
May 27, 2024
STAR Registry Unveils Promising Insights

Prof Dr Daniel Wendt on: Intraoperative hemoadsorption for antithrombotic drug removal during cardiac surgery: Initial report of the International Safe and Timely Antithrombotic Removal (STAR) Registry.

read blog post
May 21, 2024
CytoSorb’s important role in severe rhabdomyolysis requiring continuous veno-venous haemodialysis

Dr Volker Humbert on: Rapid and effective elimination of myoglobin with CytoSorb® hemoadsorber in patients with severe rhabdomyolysis.

read blog post
May 21, 2024
Unveiling the Impact of CytoSorb Therapy on Fluid Balance in Septic Shock Patients

Unveiling the Impact of CytoSorb Therapy on Fluid Balance in Septic Shock Patients Dr Jörg Scheier on: “Impact of CytoSorb Hemoadsorption Therapy on Fluid Balance in Patients with Septic Shock” Kogelmann K, Hübner T, Drüner M, Jarczak D. Journal of Clinical Medicine

read blog post
CytoSorbents

Voices around the world

world map
Critical Care
Assoc. Prof. Monir Sadat Hakemi
Tehran, Iran

It seems that applying the CytoSorb in combination with CRRT in ICU septic patients with AKI is correlated with a significant decrease in mortality.

Critical Care
Prof. Pedja Kovacevic
Banja Luka, Bosnia and Herzegovina

This case series describes potential positive effects of hemoadsorption in preventing the development of systemic hyperinflammation after vvECMO in ARDS.

Cardiovascular
Dr. Henriette Roed-Undlien
Oslo, Norway

In this in vitro study, apixaban levels were effectively reduced, and the clotting time and thrombin generation assays were normalized by the use of CytoSorb.

View All Voices